Navigation Links
Alseres Pharmaceuticals, Inc. Complies with NASDAQ Rule Regarding Recently Filed 10-K
Date:3/31/2009

ially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Forward-Looking Statements

The foregoing release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Alseres' future expectations, beliefs, intentions, goals, strategies, plans or prospects regarding the future, including the Company's ability to obtain financing, the development and commercialization of Altropane and Cethrin, the prospects of the Company's CNS and regenerative therapeutics programs, the Company's strategies to develop and commercialize axon regeneration technologies and the breadth of the Company's technologies and intellectual property portfolio. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achie
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
2. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
3. Alseres Pharmaceuticals, Inc. Raises $5 Million
4. Alseres Pharmaceuticals, Inc. Reports 2007 Financial Results and Provides Company Highlights
5. Alseres Pharmaceuticals to Host 2007 Financial Results Conference Call
6. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
7. Alseres Pharmaceuticals, Inc. to Present at Windhovers Therapeutic Area Partnerships Conference
8. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
9. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
10. Trubion Pharmaceuticals, Inc. Announces Initiation of Phase 1 Study of SBI-087 for the Treatment of Systemic Lupus Erythematosus (SLE)
11. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 1, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV ... commercialization of targeted antiviral therapies, announced today that it ... Annual Global Investment Conference sponsored by H.C. ... at The St. Regis Hotel in New ... Sapirstein , Chief Executive Officer, will provide an overview ...
(Date:9/1/2015)... Eau Claire, WI (PRWEB) , ... September 01, 2015 , ... ... 2015), Alexi Venice expertly transports the reader to a not-so-distant future faced with an ... McCallan, a beautiful professional who overcomes personal tragedy to enter the world of counterterrorism, ...
(Date:9/1/2015)... , Sept. 1, 2015 The Dohmen ... Floyd , Ph.D., MBA as Chief Science Officer ... this newly created role, Dr. Floyd will lead ... a portfolio of pre-commercial and post approval outsourced ... and medical communications.  Dr. Floyd brings decades of ...
(Date:9/1/2015)... CARY, N.C. , Sept. 1, 2015 /PRNewswire/ ... dedicated to facilitating the relationship between doctors and ... two Durham, N.C. -based venture ... financial strength and business association with Bull City ... Steve Malik , Medfusion Founder and Executive Chairman. ...
Breaking Biology Technology:ContraVir to Present at Rodman & Renshaw 17th Annual Global Investment Conference 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 2Medfusion Secures Funding to Continue Evolution and Advance Mobile Strategy 3
... FRANCISCO, Feb. 10 Jennerex, Inc. (San Francisco, ... that the journal, Nature Reviews Cancer, has published ... oncolytic poxviruses, which have,demonstrated encouraging clinical and preclinical ... issue, was authored by David H. Kirn, M.D.,president ...
... retailer launches Max Crunch bar with patented ... with protein digestion and assimilationANAHEIM, Calif., Feb. ... Nutrition today announced the launch of Max ... in the U.S. The collaboration between Max ...
... Pharmaceuticals, Inc.,(NYSE Alternext US: ANX) announced today that ... companies representing a range of,strategic transactions. The ... In December 2008, the Company announced that it ... sale or disposition of one or more of ...
Cached Biology Technology:Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic 2Nature Reviews Publishes Article About Jennerex's Multi-Mechanistic Cancer Therapeutic 3Max Muscle Introduces First-Ever Probiotics Protein Bar 2Max Muscle Introduces First-Ever Probiotics Protein Bar 3ADVENTRX Provides Update on Strategic Transaction Process 2ADVENTRX Provides Update on Strategic Transaction Process 3ADVENTRX Provides Update on Strategic Transaction Process 4
(Date:8/11/2015)... , August 11, 2015 Today, ZUK ... Already received as well as expected revenues in 2015 that relate ... FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a prominent smartphone manufacturer in ... ZUK selected FPC1 155 for ...
(Date:8/6/2015)... Aug. 6, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced collaboration with Microsoft on ... 10. Microsoft leveraged Synaptics, deep expertise in human ... Through stringent testing, Synaptics, advanced ... with Microsoft,s Precision TouchPad (PTP) specification empowering OEMs ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2Synaptics Chosen for Human Interface Co-Development on Windows 10 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... inside the nuptial gift that a potential suitor brings to ... the whole package, white silk wrappings and all, that can ... Mariana Trillo, Valentina Melo-Gonzlez and Mara Jos Albo of the ... out the first study to look at the role of ...
... matter microstructure, the communication pathways of the brain, continues ... in white matter microstructure to specific cognitive abilities in ... not include individuals from the entire life span or ... knowledge gap prompted a new study published this week ...
... Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) is pleased ... AIDS treatment and prevention programs in six districts ... for International Development (USAID) and the U.S. President,s ... services offered through EGPAF,s Strengthening Clinical Services (SCS) ...
Cached Biology News:White silk wrappings key to female spider's heart 2Your brain is fine-tuning its wiring throughout your life 2Lesotho takes new steps toward HIV/AIDS elimination 2
... interface. All the functionality of the micro1401 ... memory and more available channels of waveform ... an option for programmable front-end gain. Can ... 48 waveform inputs and from 4 to ...
... White to off-white solid. Increases the expression of ... Soluble in H 2 O. Unstable in ... RTECS EK7713840, CAS 3211-76-5, M.W. 196.1. References: ... L., and Junod, A.F. 1995. Biochem. J. ...
... This marking pen has been designed to provide a ... the specimen on a slide. This barrier creates ... within the target area on the slide. PAP ... alcohol and acetone. It can be removed, if ...
Mouse monoclonal antibody to QDPR - quinoid dihydropteridine reductase...
Biology Products: